Prolonged response to atezolizumab with bevacizumab plus chemotherapy in a patient with lung cancer harboring mutation in EGFR after Afatinib treatment: A case report

Prolonged response to atezolizumab with bevacizumab plus chemotherapy in a patient with lung cancer harboring mutation in EGFR after Afatinib treatment: A case report

Immune monotherapy is ineffective for oncogene-addicted lung cancer. This study reported the case of a patient with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation that recurred after treatment with afatinib, a tyrosine kinase inhibitor (TKI). After treatment with afatinib...

Full description

Bibliographic Details
Main Authors: Hayato Koba, Taro Yoneda, Hiroko Morita, Tsukasa Ueda, Ryo Hara, Nanao Terada, Mako Miyakawa, Hideharu Kimura, Kazuo Kasahara
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Lung cancer harboring mutation in EGFR
Afatinib
Immunotherapy
NF1
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621921000648

Internet

http://www.sciencedirect.com/science/article/pii/S2666621921000648

Similar Items